Quick Answer
Climb Bio, Inc. reported R&D Expense of $46.71 million for fiscal year 2025.
Climb Bio, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $46.71M | +225.8% |
| 2024 | $14.34M | -7.0% |
| 2023 | $15.41M | -41.2% |
| 2022 | $26.21M | +12.4% |
| 2021 | $23.32M | +166.0% |
| 2020 | $8.77M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $9.07M | +45.4% | +38.0% |
| June 30, 2025 | $6.58M | +528.6% | -62.1% |
| March 31, 2025 | $17.33M | +1488.2% | +177.7% |
| September 30, 2024 | $6.24M | +117.0% | +496.6% |
| June 30, 2024 | $1.05M | -71.6% | -4.1% |
| March 31, 2024 | $1.09M | -80.9% | -62.1% |
| September 30, 2023 | $2.88M | -32.5% | -22.0% |
| June 30, 2023 | $3.69M | -57.9% | -35.5% |
- Climb Bio, Inc. showed an increase of +225.8% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, Climb Bio, Inc.’s r&d expense has grown by 432.7% (from $8.77 million to $46.71 million).
- The most recent figure is from Climb Bio, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: